Status | Study |
Completed |
Study Name: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Condition: Recurrent Thyroid Cancer Stage IVA Follicular Thyroid Cancer Date: 2011-07-20 Interventions: Drug: pazopanib hydrochloride |
Recruiting |
Study Name: IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Condition: Thyroid Cancer Date: 2011-07-06 Interventions: Radiation: I131 1.1 GBq Radio-iodine Other Name: Sod |
Active, not recruiting |
Study Name: Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Condition: Recurrent Thyroid Gland Carcinoma Stage I Thyroid Gland Follicular Car Date: 2010-09-22 Interventions: Drug: Cediranib Maleate Given |
Completed |
Study Name: Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Condition: Head and Neck Cancer Date: 2010-07-15 Interventions: Drug: everolimus Other: laboratory biomark |
Completed |
Study Name: Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Condition: Head and Neck Cancer Date: 2010-05-05 Interventions: Drug: everolimus |
Completed |
Study Name: Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients Condition: Thyroid Neoplasms Date: 2010-04-29 Interventions: Drug: Administration of 131 iodine 100 mCi 131 iodine irradiation |
Completed |
Study Name: A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Condition: Papillary Thyroid Cancer Follicular Thyroid Cancer Date: 2010-03-22 Interventions: Drug: rosiglitazone one 4 mg d |
Withdrawn |
Study Name: S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Condition: Breast Cancer Head and Neck Cancer Lung Cancer Date: 2009-07-10 Interventions: Drug: docetaxel Drug: vandetanib |
Completed |
Study Name: Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Condition: Recurrent Thyroid Gland Carcinoma Stage III Thyroid Gland Follicular C Date: 2008-08-06 Interventions: Radiation: Fludeoxyglucose F-18 |
Completed |
Study Name: Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Condition: Papillary Thyroid Cancer Follicular Thyroid Cancer Date: 2008-04-25 Interventions: Drug: SU011248, Sutent Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total t |